Updates

13
Nov

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) submitted a letter to BlueCross BlueShield (BCBS) of Tennessee urging an expansion of cardiac PET coverage.

 

Full Text

13
Nov

GE Healthcare and Lantheus Medical Imaging have launched a second phase III clinical trial for Lantheus' flurpiridaz F-18 investigational PET radiopharmaceutical.

Full Text

13
Nov

Florbetapir-PET scans show that midlife adults with two or more vascular risk factors are significantly more likely to have greater levels of amyloid deposits in their brains later in life than peers with no such risk factors, according to a study published April 11 in the Journal of the American Medical... Read More

02
Oct

Heart disease is a danger like no other, meaning proper diagnosis is of paramount importance. PET scans have been, and continue to be, the best way to get such a diagnosis.

 

Full Text

06
Sep

POSITRON ANNOUNCES SALE OF ATTRIUS PET SCANNER

 

Niagara Falls, NY –September 5, 2018 – Positron Corporation (OTC:POSC)(the “Company”), a nuclear medicine healthcare company, is pleased to announce the sale of its Attrius PET scanner to a prominent cardiology practice in the US as they expand their services to... Read More

28
Apr

The diversification and expansion of PET imaging into cardiology and neurology are two applications expected to propel growth in PET procedure volume and equipment purchasing over the next several years, according to a new market research report from Bio-Tech Systems.

The study predicts that the approval of... Read More